Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets
Journal of Clinical Medicine · 25.03.2024 · 13 (7) · 1881
DOI: 10.3390/jcm13071881 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 25.03.2024. Verfasst von Allison B Reiss und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Biomedical Research Institute, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA. Die Arbeit wurde bisher 114-mal zitiert (Crossref) und nennt 314 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSRD VA, Herb and Evelyn Abrams Family Amyloid Research Fund.
Abstract (Originalsprache)
Chronic kidney disease (CKD) is a slowly progressive condition characterized by decreased kidney function, tubular injury, oxidative stress, and inflammation. CKD is a leading global health burden that is asymptomatic in early stages but can ultimately cause kidney failure. Its etiology is complex and involves dysregulated signaling pathways that lead to fibrosis. Transforming growth factor (TGF)-β is a central mediator in promoting transdifferentiation of polarized renal tubular epithelial cells into mesenchymal cells, resulting in irreversible kidney injury. While current therapies are limited, the search for more effective diagnostic and treatment modalities is intensive. Although biopsy with histology is the most accurate method of diagnosis and staging, imaging techniques such as diffusion-weighted magnetic resonance imaging and shear wave elastography ultrasound are less invasive ways to stage fibrosis. Current therapies such as renin-angiotensin blockers, mineralocorticoid receptor antagonists, and sodium/glucose cotransporter 2 inhibitors aim to delay progression. Newer antifibrotic agents that suppress the downstream inflammatory mediators involved in the fibrotic process are in clinical trials, and potential therapeutic targets that interfere with TGF-β signaling are being explored. Small interfering RNAs and stem cell-based therapeutics are also being evaluated. Further research and clinical studies are necessary in order to avoid dialysis and kidney transplantation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine and Biomedical Research Institute, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA.
ORCID-Profile: Allison B Reiss, Aarij Zubair, Maryann Johnson
Förderung
- CSRD VA
- Herb and Evelyn Abrams Family Amyloid Research Fund
Zitieren
APA
Reiss, A. B., Jacob, B., Zubair, A., Srivastava, A., Johnson, M., & De Leon, J. (2024). Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets. Journal of Clinical Medicine, 13(7), 1881. https://doi.org/10.3390/jcm13071881
Vancouver
Reiss AB, Jacob B, Zubair A, Srivastava A, Johnson M, De Leon J. Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets. Journal of Clinical Medicine. 2024;13(7):1881. doi:10.3390/jcm13071881
BibTeX
@article{Reiss2024,
author = {Reiss, Allison B and Jacob, Berlin and Zubair, Aarij and Srivastava, Ankita and Johnson, Maryann and De Leon, Joshua},
title = {Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets},
journal = {Journal of Clinical Medicine},
year = {2024},
volume = {13},
number = {7},
pages = {1881},
doi = {10.3390/jcm13071881}
}
EUVIMED